(Reuters) - The Gaithersburg, Maryland-based biotechnology company, which has been the subject of takeover rumors for months amid investor agitation, said it has authorized management to "evaluate whether third parties would have an interest in acquiring the company at a price and on terms that would represent a better value for its stockholders than having the company continue to execute its business plan on a stand-alone basis."
) Keywords: MEDIMMUNE CONFIRMATION/
Read more at Reuters.com Market News
) Keywords: MEDIMMUNE CONFIRMATION/
Read more at Reuters.com Market News
No comments:
Post a Comment